kabutan

SANTEN PHARMA, Apr-Dec (Cumulative 3Q) Net Income Decreases by 21%, Oct-Dec Net Income Decreases by 9%

Thu Feb 5, 2026 3:30 pm JST Earnings

4536 SANTEN PHARMACEUTICAL CO.,LTD. 【IFRS】

Earnings Report

SANTEN PHARMACEUTICAL CO.,LTD. <4536> [TSE Prime] announced its financial results (based on IFRS) after the market closed on February 5th (15:30). The consolidated net income for the cumulative third quarter of the fiscal year ending March 2026 (April to December) decreased 20.6% from the same period last year to 21.8 billion yen. Progress toward the full-year plan of 34.0 billion yen was 64.2%, also falling below the five-year average of 118.1%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the January to March period (4Q) is expected to expand 38.6% from the same period last year, reaching 12.1 billion yen.

In the most recent three-month period, from October to December (3Q), the consolidated net income decreased to 7.87 billion yen, a 9.4% decrease compared to the same period last year. The operating profit margin decreased from 14.8% in the same period last year to 14.1%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 222,833 36,157 33,559 26,613 72.3 112.3 Feb 8, 2024 IFRS
Apr - Dec, 2024 222,773 35,195 35,309 27,465 78.2 74.4 Feb 6, 2025 IFRS
Apr - Dec, 2025 210,763 28,219 28,076 21,816 66.2 ー Feb 5, 2026 IFRS
YoY -5.4% -19.8% -20.5% -20.6% -15.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 153,600 23,007 23,642 17,484 50.1 19 May 13, 2025 IFRS
Oct - Mar, 2025 Guidance 156,121 26,085 ー 20,060 62.4 19 Nov 6, 2025 IFRS
YoY +1.6% +13.4% － +14.7% +24.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 301,965 38,541 29,874 26,642 72.6 33 May 9, 2024 IFRS
Mar, 2025 300,004 46,880 47,481 36,256 104.0 36 May 13, 2025 IFRS
Mar, 2026 Guidance 294,000 44,000 ー 34,000 105.7 38 Aug 7, 2025 IFRS
YoY -2.0% -6.1% － -6.2% +1.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 76,369 11,322 11,470 8,693 24.8 14.8 Feb 6, 2025 IFRS
Jan - Mar, 2025 77,231 11,685 12,172 8,791 25.2 15.1 May 13, 2025 IFRS
Apr - Jun, 2025 68,737 7,573 7,450 5,878 17.3 11.0 Aug 7, 2025 IFRS
Jul - Sep, 2025 69,142 10,342 10,184 8,062 24.2 15.0 Nov 6, 2025 IFRS
Oct - Dec, 2025 72,884 10,304 10,442 7,876 23.9 14.1 Feb 5, 2026 IFRS
YoY -4.6% -9.0% -9.0% -9.4% -3.5%

Related Articles